Beverly Tchang, Associate Professor of Clinical Medicine at Weill Cornell Medicine in New York and triple board-certified physician in Internal Medicine, Endocrinology, and Obesity Medicine
The drug has risen to recognition thanks to one side effect: weight loss
A 2021 study found that -glucan barley supplementation increased GLP-1 secretion and improved glucose tolerance in an obesity mice model study, highlighting its metabolic benefits
470 Recently, studies have shown that the GLP-1RA Meg peptide also enters the ejection fraction reserve following heart failure therapy
AOD 9604 Clinical Trial History: What the Research Actually Shows Six Phase I and Phase II clinical trials were conducted by Metabolic Pharmaceuticals Ltd., enrolling approximately 900 participants in total
World population propects: the 2015 revision, key findings and advance tables